会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Methods for pre-stressing and capping bioprosthetic tissue
    • 预应力和覆盖生物假体组织的方法
    • US09101691B2
    • 2015-08-11
    • US12135507
    • 2008-06-09
    • Jim DavidsonJeff DoveDarin Dobler
    • Jim DavidsonJeff DoveDarin Dobler
    • A61L27/00A61L27/36A61L27/50
    • A61L27/3625A61F2/2412A61F2210/0004A61F2210/0076A61L27/3683A61L27/3687A61L27/3691A61L27/507A61L2400/02A61L2430/20A61L2430/40
    • A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification is disclosed. The method includes preconditioning, pre-stressing, or pre-damaging fixed bioprosthetic tissue in a manner that mimics the damage associated with post-implant use, while, and/or subsequently applying a calcification mitigant such as a capping agent or a linking agent to the damaged tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the damage process (service stress) and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. The linking agent will act as an elastic reinforcement or shock-absorbing spring element in the tissue structure at the site of damage from the pre-stressing. In one method, tissue leaflets in assembled bioprosthetic heart valves are preconditioned by simulating actual flow conditions for a predetermined number of cycles, during or after which the valve is exposed to the capping agent.
    • 公开了用于植入物或组装的生物假体心脏瓣膜以减少体内钙化的生物假体组织的治疗。 该方法包括以模拟与植入后使用相关的损伤的方式预处理,预应激或预破坏固定的生物假体组织,同时和/或随后将钙化缓解剂如封端剂或连接剂施用于 受损的组织。 封端剂抑制由损伤过程(服务压力)暴露或产生的组织中的结合位点的形成,否则将在植入时吸引钙,磷酸盐,免疫原性因子或其它钙化前体。 连接剂将在预应力损伤部位作为组织结构中的弹性增强或减震弹簧元件。 在一种方法中,组装的生物假体心脏瓣膜中的组织小叶通过在瓣膜暴露于封盖剂中或之后模拟实际流动条件预定数量的循环来预处理。
    • 6. 发明申请
    • METHODS FOR PRE-STRESSING AND CAPPING BIOPROSTHETIC TISSUE
    • 预应力和覆盖生物组织的方法
    • US20080302372A1
    • 2008-12-11
    • US12135507
    • 2008-06-09
    • Jim DavidsonJeff DoveDarin Dobler
    • Jim DavidsonJeff DoveDarin Dobler
    • A61L27/00A61L27/28A61L27/50
    • A61L27/3625A61F2/2412A61F2210/0004A61F2210/0076A61L27/3683A61L27/3687A61L27/3691A61L27/507A61L2400/02A61L2430/20A61L2430/40
    • A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification is disclosed. The method includes preconditioning, pre-stressing, or pre-damaging fixed bioprosthetic tissue in a manner that mimics the damage associated with post-implant use, while, and/or subsequently applying a calcification mitigant such as a capping agent or a linking agent to the damaged tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the damage process (service stress) and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. The linking agent will act as an elastic reinforcement or shock-absorbing spring element in the tissue structure at the site of damage from the pre-stressing. In one method, tissue leaflets in assembled bioprosthetic heart valves are preconditioned by simulating actual flow conditions for a predetermined number of cycles, during or after which the valve is exposed to the capping agent.
    • 公开了用于植入物或组装的生物假体心脏瓣膜以减少体内钙化的生物假体组织的治疗。 该方法包括以模拟与植入后使用相关的损伤的方式预处理,预应激或预破坏固定的生物假体组织,同时和/或随后将钙化缓解剂如封端剂或连接剂施用于 受损的组织。 封端剂抑制由损伤过程(服务压力)暴露或产生的组织中的结合位点的形成,否则将在植入时吸引钙,磷酸盐,免疫原性因子或其它钙化前体。 连接剂将在预应力损伤部位作为组织结构中的弹性增强或减震弹簧元件。 在一种方法中,组装的生物假体心脏瓣膜中的组织小叶通过在瓣膜暴露于封盖剂中或之后模拟实际流动条件预定数量的循环来预处理。